Skip to main content
. 2020 Jul 1;19(3):277–280. doi: 10.4103/wjnm.WJNM_65_19

Figure 1.

Figure 1

Pretreatment positron emission tomography scan demonstrating primary sites of disease (arrows) on anterior maximum intensity projection (MIP) image (a). Posttreatment positron emission tomography scan anterior (b) and oblique (c) MIP images showing complete metabolic resolution in the sites of primary disease but new fluorodeoxyglucose-avid lesions (arrowheads)